Abstract 207P
Background
Diabetes mellitus is considered as a potential risk factor for breast cancer, yet the relationship between diabetic background retinopathy (DBR) and breast cancer remains uncertain. This study leverages mendelian randomization (MR) to explore the genetic link between diabetic background retinopathy (DBR) and estrogen receptor-positive (ER+) breast cancer, highlighting the connection with diabetes-related conditions.
Methods
We acquired summary data from a genome-wide association study (GWAS) concerning DBR in the European population, with a focus on their relationship with ER+ breast cancer. We performed two-sample MR analysis with multiple approaches to evaluate the potential causal associations between DBR and ER+ breast cancer. Pleiotropy and Cochran's Q tests were utilized to determine horizontal pleiotropy and heterogeneity.
Results
Of the 205,044 participants (2,026 DBR cases) from FinnGenn, we identified 8 single nucleotide polymorphisms (SNPs) associated with the risk of ER+ breast cancer (69,501 ER+ breast cancer cases from iCOGS). The MR analysis showed a suggestive association between DBR susceptibility and ER+ breast cancer (weight median odds ratio [OR]: 0.971, 95% confidence interval [CI]: 0.955-0.987, P = 0.0006; simple mode OR: 0.964, P = 0.043; weight mode OR: 0.971, P = 0.015). The effect size estimate (β) for weight median model was -0.0294, indicating a 2.94% decrease in the odds of ER+ breast cancer per unit increase in genetically predicted DBR. Sensitivity analyses are consistent with the results, manifesting that our findings were convincing and robust.
Conclusions
These finding suggests that a potential inverse relationship between DBR and the risk of ER+ breast cancer. These findings could significantly impact screening and prevention strategies for diabetic populations, emphasizing the need for further research into this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
225P - Nivolumab for cancer of unknown primary (CUP): Clinical efficacy and biomarker analysis from NivoCUP2 expanded access program (WJOG14620M)
Presenter: Junko Tanizaki
Session: Poster session 09
226TiP - CLEAR-Me: Interception trial to detect and clear molecular residual disease in patients with high-risk melanoma
Presenter: Erick Saldanha
Session: Poster session 09
227TiP - A phase II, open label, randomized, non-comparative cohorts study of adjuvant atezolizumab or atezolizumab plus tiragolumab in solid tumors with resectable disease with intermediate-high risk of recurrence and high tumor mutational burden (TMB-H) or microsatellite instability (MSI-H)
Presenter: Guillermo Antonio De Velasco Oria
Session: Poster session 09
228TiP - FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs
Presenter: Mika Mustonen
Session: Poster session 09
229TiP - A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies
Presenter: Robert Walsh
Session: Poster session 09
230TiP - Exploring mechanisms of action and resistance in innovate cancer therapies: The UNLOCK program
Presenter: Beatriz Alonso de Castro
Session: Poster session 09
694P - Sequential high-dose-chemotherapy with 4 cycles paclitaxel, ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory male germ cell cancer: Final results with 15.8 years follow-up
Presenter: Hans Joachim Schmoll
Session: Poster session 09
695P - Assessment of the utility of CT scans in the long-term follow-up of metastatic non-seminomatous germ cell tumours (mNSGCT): The Late CT study
Presenter: Deep Chakrabarti
Session: Poster session 09
696P - Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma
Presenter: David Pfister
Session: Poster session 09
697P - The Empower Pathway overview: An innovative approach to delivering personalised care for testicular cancer survivors
Presenter: Robert Holwell
Session: Poster session 09